Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

2.990 -0.170 (-5.38%)
Streaming Delayed Price Updated: 2:18 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,040,807
Open 3.130
Bid (Size) 2.990 (15)
Ask (Size) 3.000 (12)
Prev. Close 3.160
Today's Range 2.980 - 3.130
52wk Range 3.080 - 21.88
Shares Outstanding 51,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
Opioid Overdose Treatment: Walgreens To Stock FDA-Approved NARCAN Spray
Walgreens Boots Alliance Inc (NASDAQ: WBA) said 
Via Benzinga

Performance

YTD
-75.12%
-75.12%
1 Month
-37.97%
-37.97%
3 Month
-60.50%
-60.50%
6 Month
-69.46%
-69.46%
1 Year
-85.81%
-85.81%

More News

Read More
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
From Emergent BioSolutions
Via GlobeNewswire
Why Emergent BioSolutions Stock Is Tumbling Today
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2023
Via Benzinga
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Exposures Product Safety
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
PureCycle Technologies, Canadian Solar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Emergent BioSolutions (EBS) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
From Emergent BioSolutions
Via GlobeNewswire
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Emergent Biosolutions Stock Is Surging After The Close
Via Benzinga
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
Potential Delay In iPhone 15 Debut Could Impact Apple's Margins, Meta's Threads App Faces User Exodus, Microsoft CEO Satya Nadella's Earnings Exceed $1B: Today's Top Stories
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Emergent BioSolutions Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Emergent BioSolutions' Two-Dose Anthrax Vaccine Secures FDA Nod; Shares Jump
Via Benzinga
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.